Biotech Sector Ignites After-Hours: Clinical Wins and FDA Support Fuel Sharp Gains

Biotech equities demonstrated pronounced volatility in extended trading hours, with several names staging impressive rebounds following daytime selloffs. A combination of promising clinical trial data, regulatory approvals, and capital raise announcements provided the momentum, reflecting key catalysts that market participants are monitoring with heightened interest.

Strong Movers Lead the Charge

Stoke Therapeutics, Inc. (STOK) emerged as one of the most significant gainers, surging to $33.95 in after-hours trading, representing an 11.42% appreciation from its regular-session close of $30.47 (-7.67%). The recovery was bolstered by clinical data presentations conducted in collaboration with Biogen (BIIB) at the 2025 AES Annual Meeting, which demonstrated encouraging results for zorevunersen as a potential treatment for Dravet syndrome.

Alpha Tau Medical Ltd. (DRTS) delivered a standout performance, with shares climbing to $5.30 during extended hours—a 25.26% jump or $1.07 gain above the 4:00 PM EST regular close of $4.23 (+8.74%). The company’s announcement that initial patient enrollment has commenced in its pilot investigation of Alpha DaRT technology for treating recurrent glioblastoma multiforme (GBM) provided the underlying support for the tau symbol of innovation in precision oncology.

Secondary Catalysts Driving Momentum

COMPASS Pathways plc (CMPS) ascended to $6.64 (+4.40%) during after-hours trading, building on a regular-session finish of $6.36 (+0.95%). Management disclosed upcoming plans for a webinar scheduled for January 7, 2026, focusing on commercial strategy development for treatment-resistant depression (TRD) and clinical advancement plans for post-traumatic stress disorder (PTSD) trials.

Senti Biosciences, Inc. (SNTI) posted an intriguing reversal, rallying to $1.60 (+3.92%) after-hours despite a significant regular-session decline to $1.54 (-35.56%). The turnaround was sparked by FDA designation of Rapid Modernization of Approval Pathway (RMAT) status granted to SENTI-202, the company’s proprietary CAR-NK cell immunotherapy targeting acute myeloid leukemia and associated hematologic malignancies.

Absci Corp. (ABSI) gained modestly to $3.65 (+3.69%), extending a regular-session appreciation of $3.52 (+2.03%). While no breaking developments emerged Tuesday, the company’s December 4 announcement regarding first volunteer administration in its Phase 1/2a HEADLINE trial of ABS-201, an anti-PRLR antibody candidate, continues to resonate with the investment community.

Capital Activity and Secondary Adjustments

TuHURA Biosciences, Inc. (HURA) posted a marginal after-hours gain of $1.18 (+0.85%), despite enduring a steep regular-session retreat to $1.17 (-40.91%). The company unveiled a registered direct offering comprising 9.4 million shares paired with warrant instruments, priced at $1.65 per unit.

Maravai LifeSciences Holdings, Inc. (MRVI) advanced to $3.86 (+7.32%) in extended trading, following a regular close of $3.69 (+2.22%), though company-specific developments were not publicly disclosed on the trading day.

The biotech sector’s after-hours activity underscores the market’s responsiveness to clinical achievements, regulatory recognition, and strategic capital deployment—key drivers that continue to shape investment flows within the space.